Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
| Autor: | Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW, COMMA (COMplement inhibition in Myocardial infarction treated with Angioplasty) Investigators, Granger, Christopher B, Mahaffey, Kenneth W, Weaver, W Douglas, Theroux, Pierre, Hochman, Judith S, Filloon, Thomas G, Rollins, Scott, Todaro, Thomas G |
|---|---|
| Zdroj: | Circulation; 2003 Sep 9, Vol. 108 Issue 10, p1184-1190, 7p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|